Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Alison F. Munro, Annette Bartels, Eva Balslev, Christopher J. Twelves, David A Cameron, Nils Brünner, John Ms Bartlett

    4 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?'. Together they form a unique fingerprint.

    Medicine & Life Sciences